Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Blood (2024) 144 (Supplement 1): 685.

https://doi.org/10.1182/blood-2024-194414

Published: 2024

Journal Articles

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2024-199170

Published: 2024

Journal Articles

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Alaa Ali, Nausheen Ahmed, Soyoung Kim, Matthew Bye, Sayeef Mirza, Alex Gordon Sieg, Christopher Strouse, Kalyan Nadiminti, Priyanka A. Pophali, Rammurti T. Kamble, Lohith Gowda, Cameron J. Turtle, Christine L. Phillips, Marcelo C. Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop

Blood (2024) 144 (Supplement 1): 71.

https://doi.org/10.1182/blood-2024-200269

Published: 2024

Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 214.

https://doi.org/10.1182/blood-2024-198218

Published: 2024

Journal Articles

Full Body Screening Computed Tomography Prior to Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institution Experience from an Academic Center

Danielle McQuinn, Lauren Racki, Vaishalee P Kenkre, Matthew James Brunner, Zhubin J. Gahvari, Ryan J Mattison, Aric C. Hall, Kalyan Nadiminti

Blood (2023) 142 (Supplement 1): 378.

https://doi.org/10.1182/blood-2023-178878

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Kalyan Nadiminti, M Hasib Sidiqi, MBBS, Kapil Meleveedu, MDMBBS, Hassan B. Alkhateeb, MD, Aref Al-Kali, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Shaji K. Kumar, MD, Mrinal M Patnaik, MDMBBS, Morie A. Gertz, MD, Dong Chen, MD PhD, Mithun Vinod Shah, MD PhD

Blood (2019) 134 (Supplement_1): 4560.

https://doi.org/10.1182/blood-2019-123065

Published: 2019

Journal Articles

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Kalyan Nadiminti, Abhishek A Mangaonkar, MBBS, Kimberly J. Langer, D.N.P., C.N.P., Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Michelle A Elliott, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mark Litzow, MD, William J Hogan, MB, BCh, Saad S. Kenderian, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3300.

https://doi.org/10.1182/blood-2019-121742

Published: 2019

Journal Articles

Impact of Absolute Lymphocyte Count at Time of Antithymocyte Globulin on Outcomes of Allogeneic Unrelated Hematopoietic Cell Transplantation with Busulfan and Fludarabine Myeloablative Conditioning

Adithya Chennamadhavuni, MBBS, Kalyan Nadiminti, Lindsay Dozeman, Umar Farooq, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Sarah Mott, MS, Margarida Magalhaes Silverman, MD

Blood (2019) 134 (Supplement_1): 5671.

https://doi.org/10.1182/blood-2019-128186

Published: 2019

Journal Articles

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Sarah L Mott, Jillna Claus, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Guido J. Tricot, MD PhD

Blood (2018) 132 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2018-99-113890

Published: 2018

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Gabrielle Berns, Jillna Claus, Sarah L Mott, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MD FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 2153.

https://doi.org/10.1182/blood-2018-99-118443

Published: 2018

Journal Articles

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Li Can, MD, Kalyan Nadiminti, Yuqi Zhu, Yogesh Jethava, MBBS, MD FRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 5612.

https://doi.org/10.1182/blood-2018-99-115099

Published: 2018

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Lindsay Dozeman, Annick Tricot, Allyson Schultz, Sheila Ouverson, Fenghuang Zhan, MD PhD, Margarida Silverman, MD, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP

Blood (2017) 130 (Supplement 1): 4543.

https://doi.org/10.1182/blood.V130.Suppl_1.4543.4543

Published: 2017

Journal Articles

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

Xin Zhan, Reinaldo Franqui-Machin, Kalyan Nadiminti, MD, Huojun Cao, Brad A. Amendt, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 1785.

https://doi.org/10.1182/blood.V130.Suppl_1.1785.1785

Published: 2017

Journal Articles

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Kalyan Nadiminti, MD, Umar Farooq, MD, Lindsay Dozeman, Sarah Mott, MS, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Margarida Silverman, MD

Blood (2017) 130 (Supplement 1): 3281.

https://doi.org/10.1182/blood.V130.Suppl_1.3281.3281

Published: 2017

Journal Articles

Potential Pitfalls of Serum Free Light Chain Analysis to Assess Treatment Response for Multiple Myeloma

Kamal Kant Singh Abbi, MBBS, Guido J Tricot, MD PhD, Margarida Silverman, MD, Kalyan Nadiminti, MD, Matthew Krasowski

Blood (2015) 126 (23): 5308.

https://doi.org/10.1182/blood.V126.23.5308.5308

Published: 2015

Journal Articles

Salvage Tandem Autologous Stem Cell Transplant with Consolidation for Relapsed Multiple Myeloma

Kamal Kant Singh Abbi, MBBS, Sonya Behrends, Margarida Silverman, Umar Farooq, MD, Kalyan Nadiminti, MD, Guido J Tricot, MD PhD

Blood (2015) 126 (23): 5497.

https://doi.org/10.1182/blood.V126.23.5497.5497

Published: 2015

Journal Articles

Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)

Kalyan Nadiminti, MD, Kamal Kant Singh Abbi, MBBS, Annick Tricot, Allyson Schultz, Lindsay Dozeman, Sarah L Mott, MS, Fenghuang Zhan, MD PhD, Guido J Tricot, MD PhD

Blood (2015) 126 (23): 1971.

https://doi.org/10.1182/blood.V126.23.1971.1971

Published: 2015

NARROW

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Full Body Screening Computed Tomography Prior to Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institution Experience from an Academic Center

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Impact of Absolute Lymphocyte Count at Time of Antithymocyte Globulin on Outcomes of Allogeneic Unrelated Hematopoietic Cell Transplantation with Busulfan and Fludarabine Myeloablative Conditioning

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Potential Pitfalls of Serum Free Light Chain Analysis to Assess Treatment Response for Multiple Myeloma

Salvage Tandem Autologous Stem Cell Transplant with Consolidation for Relapsed Multiple Myeloma

Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only